Compare the Operating Condition of Two Levels of Muscle Relaxation on Facial Nerve MEP Monitoring in CPA Surgery

Intraoperative Monitoring of Facial Nerve in Patients Undergoing Cerbellopontine Angle Tumer Resection Using Partial Versus no Neuromuscular Block

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04148534

Enrollment

Registered

2019-11-01

Start date

2019-11-01

Completion date

2020-11-15

Last updated

2022-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebellopontine Angle Tumor

Brief summary

compare the operating condition of two different levels of muscle relaxation on facial nerve monitoring using transcranial motor evocked potential in CPA surgery . * To Estimate End to start facial nerve MEP amplitude ratio * To determine the effect of neuromuscular relaxant degrees on recovery and * Assessment of propofol doses needed for enhancement of early recovery and ambulation.

Detailed description

40 Patients aged from 18-60 years old undergoing Cerebellopontine angle surgery. Patients will be one of two groups: Both Induction will be accomplished with fentanyl, propofol , rocronium infusion will be given randomly to one of the groups. Depth of anaesthesia, neurotransmitter monitoring and facial nerve neurophysiological monitoring will be done.

Interventions

DRUGRocroniom, Non Depolarizing Muscle Relaxant

compare the operating condition of two different levels of muscle relaxation on facial nerve monitoring using transcranial motor evocked potential in CPA surgery

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SCREENING

Masking

TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Inclusion criteria

* Patients age between \>18 and\<60. * Patients scheduled for neurosurgical CPA surgeries * Ability to sign the consent * ASA classification I, II

Exclusion criteria

* ASA \> II * Hemodynamically unstable * Disease affecting neuromuscular transmission (myasthenia gravies ...etc.) * GCS \< 15. * Any cardiac patient (ischemic heart disease - cardiomyopathy...etc.)

Design outcomes

Primary

Measure	Time frame	Description
End to start facial nerve MEP amplitude ratio.	6 to 8 month	TCMEP recording will begin (1) prior to skin incision as baseline amplitude before muscle relaxant be taken for intubation (2) at Dural closure and end \\start amplitude ratio will be calculated.

Secondary

Measure	Time frame	Description
number of hypotension episodes and the use of vasopressors	6 to 8 month	hemodynamic condition
Total volume of propofol and fentanyl infused	6 to 8 month	Calculate dose consumption

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026